dc.contributor.author | Küblbeck, Jenni | |
dc.contributor.author | Vuorio, Taina | |
dc.contributor.author | Niskanen, Jonna | |
dc.contributor.author | Fortino, Vittorio | |
dc.contributor.author | Braeunin, Albert | |
dc.contributor.author | Abass, Khaled | |
dc.contributor.author | Rautio, Arja | |
dc.contributor.author | Hakkola, Jukka | |
dc.contributor.author | Honkakoski, Paavo | |
dc.contributor.author | Levonen, Anna-Liisa | |
dc.date.accessioned | 2020-05-08T07:53:05Z | |
dc.date.available | 2020-05-08T07:53:05Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | https://erepo.uef.fi/handle/123456789/8116 | |
dc.description.abstract | Endocrine disruptors (EDs) are defined as chemicals that mimic, block, or interfere with
hormones in the body’s endocrine systems and have been associated with a diverse array of health
issues. The concept of endocrine disruption has recently been extended to metabolic alterations
that may result in diseases, such as obesity, diabetes, and fatty liver disease, and constitute an
increasing health concern worldwide. However, while epidemiological and experimental data
on the close association of EDs and adverse metabolic e ects are mounting, predictive methods
and models to evaluate the detailed mechanisms and pathways behind these observed e ects are
lacking, thus restricting the regulatory risk assessment of EDs. The EDCMET (Metabolic e ects of
Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways) project
brings together systems toxicologists; experimental biologists with a thorough understanding of the
molecular mechanisms of metabolic disease and comprehensive in vitro and in vivo methodological
skills; and, ultimately, epidemiologists linking environmental exposure to adverse metabolic outcomes.
During its 5-year journey, EDCMET aims to identify novel ED mechanisms of action, to generate
(pre)validated test methods to assess the metabolic e ects of Eds, and to predict emergent adverse
biological phenotypes by following the adverse outcome pathway (AOP) paradigm. | |
dc.language.iso | englanti | |
dc.publisher | MDPI AG | |
dc.relation.ispartofseries | International journal of molecular sciences | |
dc.relation.uri | http://dx.doi.org/10.3390/ijms21083021 | |
dc.rights | CC BY 4.0 | |
dc.subject | endocrine disruptors (EDs) | |
dc.subject | nuclear receptors (NRs) | |
dc.subject | metabolism | |
dc.subject | metabolic syndrome | |
dc.subject | obesity | |
dc.subject | risk assessment | |
dc.subject | human health | |
dc.subject | adverse outcome pathway (AOP) | |
dc.subject | assay validation | |
dc.title | The EDCMET project: Metabolic effects of endocrine disruptors | |
dc.description.version | published version | |
dc.contributor.department | A.I. Virtanen -instituutti | |
dc.contributor.department | School of Medicine / Biomedicine,School of Pharmacy, Activities | |
uef.solecris.id | 70219529 | en |
dc.type.publication | Tieteelliset aikakauslehtiartikkelit | |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020-EU.3.1.1./825762/EU/Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways/EDCMET | |
dc.relation.doi | 10.3390/ijms21083021 | |
dc.description.reviewstatus | peerReviewed | |
dc.publisher.country | Sveitsi | |
dc.relation.articlenumber | 3021 | |
dc.relation.issn | 1661-6596 | |
dc.relation.issue | 8 | |
dc.relation.volume | 21 | |
dc.rights.accesslevel | openAccess | |
dc.type.okm | B1 | |
uef.solecris.openaccess | Open access -julkaisukanavassa ilmestynyt julkaisu | |
dc.rights.copyright | © The authors | |
dc.type.displayType | article | en |
dc.type.displayType | artikkeli | fi |
dc.rights.url | https://creativecommons.org/licenses/by/4.0/ | |